A Study of Combination Bicalutamide and Raloxifene for Patients With Castration‐Resistant Prostate Cancer
@article{Ho2017ASO, title={A Study of Combination Bicalutamide and Raloxifene for Patients With Castration‐Resistant Prostate Cancer}, author={T. Ho and R. N{\'u}{\~n}ez-Nateras and Yue-xian Hou and A. Bryce and D. Northfelt and A. Dueck and B. Wong and M. Stanton and R. Joseph and E. Castle}, journal={Clinical Genitourinary Cancer}, year={2017}, volume={15}, pages={196–202.e1} }
Micro‐Abstract A study to evaluate the toxicity of combination bicalutamide and raloxifene was conducted in patients with prostate cancer. No grade 3 or 4 adverse events occurred, and no dose reductions were required. The patient assessment of quality of life showed no statistically significant changes. The combination of bicalutamide and raloxifene treatment was well tolerated. Background: Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER‐&agr; and ER‐&bgr;, and estrogen‐based… Expand
Figures, Tables, and Topics from this paper
4 Citations
A Systematic Study of the Impact of Estrogens and Selective Estrogen Receptor Modulators on Prostate Cancer Cell Proliferation
- Medicine
- Scientific Reports
- 2020
- 1
- PDF
Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine
- Medicine
- Cancers
- 2018
- 17
- PDF
References
SHOWING 1-10 OF 55 REFERENCES
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
- Medicine
- Clinical cancer research : an official journal of the American Association for Cancer Research
- 1999
- 91
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
- Biology, Medicine
- Cancer research
- 2002
- 107
Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).
- Medicine
- Urology
- 2001
- 104
Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial
- Medicine
- BJU international
- 2006
- 43
Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
- Medicine
- The Journal of urology
- 2007
- 22
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.
- Medicine
- Urology
- 1998
- 175
Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia.
- Medicine
- Clinical prostate cancer
- 2003
- 52
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
- Medicine
- Clinical genitourinary cancer
- 2012
- 13
Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptorα and β
- Biology, Medicine
- Journal of cellular physiology
- 2011
- 37